MedTrace Logo

Novel ECCO2R Device for Hypercapnic Respiratory Failure

NCT05316532 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2023-12-28

No results posted yet for this study

Summary

The objective of this study is to assess the efficacy and safety of this new Prismalung+ membrane in its intended clinical setting by demonstrating a reduction in ventilatory parameters and pulmonary energy load or the successful maintenance of spontaneous breathing, respectively, the absence of the need to initiate vv-ECMO therapy, and initial survival.

Conditions

  • Hypercapnic Respiratory Failure

Interventions

DEVICE

Prismalung + treatment

Low-flow extracorporeal CO2 removal with or without concurrent continuous renal replacement therapy

Sponsors & Collaborators

  • Triemli Hospital, Switzerland

    collaborator UNKNOWN

  • Kantonsspital St. Gallen, St. Gallen, Switzerland

    collaborator UNKNOWN

  • Baxter International Foundation

    collaborator UNKNOWN

  • University of Zurich

    lead OTHER

Principal Investigators

  • Matthias P Matthias, PD Dr. med. · University of Zurich

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-05
Primary Completion
2024-12-31
Completion
2025-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05316532 on ClinicalTrials.gov